CANCER, vol.121, no.9, pp.1405-1413, 2015 (SCI-Expanded)
BACKGROUNDThe objectives of this study were to provide sunitinib to patients with gastrointestinal stromal tumor (GIST) who were otherwise unable to obtain it and to collect broad safety and efficacy data from a large population of patients with advanced GIST after imatinib failure.